{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-137551","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2022-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.654192+00:00","generated_at":"2026-06-26T01:31:47.638154+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Intellia appoints Muna Bhanji as Class I director, expanding board to nine","bullets":["Muna Bhanji appointed to newly created Class I director seat, board expands from 8 to 9 members.","Bhanji is founder of TIBA Global Access, former 30-year Merck senior VP for global market access & policy.","Received option for 11,700 shares at $50.29/exercise price and 7,954 RSUs, vesting over 3 years.","Term expires at 2023 annual meeting; Bhanji deemed independent under Nasdaq standards."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-137551","json":"https://secwatch.observer/filing/0001193125-22-137551.json","markdown":"https://secwatch.observer/filing/0001193125-22-137551.md","text":"https://secwatch.observer/filing/0001193125-22-137551.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312522137551/0001193125-22-137551-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312522137551/d317082d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T01:31:47.638154+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9205a7d7ee","claim":"Muna Bhanji was appointed as Director at Intellia Therapeutics, Inc..","evidence_excerpt":"On April 28, 2022, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Intellia Therapeutics, Inc. (the “Company”), the Board appointed Muna Bhanji, as a Class I director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312522137551/0001193125-22-137551-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}